NoJieBei Biotechnology Secures $30 Million Series A Financing to Advance Multiple Gene Therapy Programs

VCBeat (WeChat ID: vcbeat) has learned that Suzhou NoJieBei Biotechnology Co., Ltd. (NGGT, hereinafter referred to as NoJieBei) recently announced the completion of a $30 million Series A financing round. The round was led by Yipu Capital, with participation from Weidu Capital and existing investors Northern Light Venture Capital and Yuan Sheng Venture Capital. The proceeds will be primarily used to prepare clinical products for the company’s multiple gene therapy pipelines and to construct cGMP manufacturing facilities.

NoJieBei was established in March 2020, co-founded by seasoned scientists and entrepreneurs in the field of gene therapy, with a commitment to becoming a globally leading gene therapy company with international influence. The company has achieved comprehensive success across the entire industry chain, including early-stage development of gene therapy projects, large-scale preparation and manufacturing processes for viral vectors, establishment of quality standards, conduct of international multi-center clinical trials, and regulatory submissions for the market approval of gene therapy products. Leveraging its proprietary “One Target, Two Warheads” technology platform, NoJieBei provides effective therapeutic solutions for various genetic diseases that currently lack adequate treatment options worldwide. The team possesses internationally leading and extensive industrialization experience, having led or participated in process development, quality standard establishment, and clinical trial applications for ten projects; among these, one product has been commercially launched, and five are in Phase II/III clinical trials. The company aims to develop more safe, effective, and accessible gene therapy drugs to benefit a broader patient population.

Dr. Jiang Lixin, Founder and CEO of the company, stated: “We are deeply grateful to the outstanding investment institutions in the pharmaceutical sector for their trust and support in NoJieBei. The successful completion of this financing round will lay a solid foundation for the construction of NoJieBei’s large-scale cGMP production technology platform for gene therapy vectors, significantly accelerating our product development progress. Gene therapy is one of the most promising and attractive fields in biotechnology. Members of my team and I have personally participated in the research and development of multiple world-leading gene therapy products from our respective professional roles. These projects have covered genetic disorders affecting the hematopoietic, ophthalmic, and nervous systems, as well as infectious diseases. We have not only witnessed the advancements and evolution of gene therapy technologies but also accumulated extensive professional expertise and technical know-how. As we embark on this new journey with the NoJieBei platform, our team members are committed to leveraging innovative thinking, a global perspective, and rich industry experience to develop more and better gene therapy products, jointly advancing the field of gene therapy and contributing to human health.”

Dr. Qu Guang, Founder and COO of the company, stated, “Over the past few decades, the gene therapy industry has experienced significant ups and downs. Looking back after more than twenty years, the advances in science and technology have been tremendous, truly inspiring awe. I have also been fortunate to participate in or lead process development for several gene therapy projects at Avigen and Spark Therapeutics, witnessing firsthand the commercialization of these products and their benefits to patients. Gene therapy has evolved from academic research projects into a thriving new field of drug development, treating diseases and benefiting humanity. We are privileged to be part of this journey, and we believe that in another ten or twenty years, the landscape will be even more promising.”

Lin Xianghong, Founding Partner of Wing Capital, stated, “As one of the most promising biotechnologies, gene therapy represents a field in which we are honored to continue our participation and lead this financing round. The team at NoJieBei boasts highly successful industrialization experience, along with a global perspective and capabilities in the gene therapy sector. We are eager to support the NoJieBei team, driven by entrepreneurial passion and professional ideals, as they leverage Suzhou as their starting point to embrace a global outlook, delivering more and better therapeutic solutions for industry advancement and patients. We hope the team will accelerate the R&D and industrialization of its product pipeline, and we remain committed to providing comprehensive support throughout the company’s future development.”

Deng Feng, Founding Managing Partner of Northern Light Venture Capital, stated, “Gene therapy is a sector we are firmly bullish on and a key area of our strategic focus. NoJieBei is the third gene therapy company invested in by Northern Light. While investment in the gene therapy space has heated up significantly in recent years, genetic element engineering and the establishment of manufacturing processes remain critical challenges and barriers to entry in this field. NoJieBei boasts one of the few founding teams in China with extensive experience in production and industrialization. We were privileged to participate deeply in the company’s development from the angel round, and we believe that under the leadership of Dr. Jiang and Dr. Qu, the company will provide effective therapeutic options for more patients with genetic diseases, thereby benefiting patients.”

Yipu Capital was established in 2016 as a wholly-owned private equity fund management platform under Suzhou Private Capital Investment Holding Co., Ltd. The core management team of Yipu Capital has nearly two decades of practical experience in private equity investment, specializing in leveraging capital to foster symbiotic industrial development. The firm has accumulated extensive investment experience and a track record of successful cases in strategic emerging industries such as biopharmaceuticals and next-generation information technology. Adhering to innovative investment management principles, Yipu Capital focuses on sectors that align with China’s long-term sustainable economic development, structural transformation and adjustment, and national policy support. Its primary investment areas include biopharmaceuticals, next-generation information technology, and branded consumer goods.

Northern Light Venture Capital was founded by Mr. Deng Feng in 2005, with the mission of “empowering world-class Chinese entrepreneurs and nurturing world-class Chinese enterprises.” It has long focused on investing in early-stage, technology-driven innovative companies. To date, it has invested in nearly 400 outstanding enterprises in the TMT, advanced technology, and healthcare sectors. Northern Light Venture Capital entered the healthcare sector in 2009. Over the past decade-plus, its investments have spanned multiple sub-sectors, including medical devices, in vitro diagnostics (IVD), biopharmaceuticals, healthcare services, and E-Health, covering virtually the entire industry chain. The firm has invested in more than 60 companies, including CITIC Pharmaceutical, BGI Genomics, Burning Rock Biotech, Zeltis Pharmaceuticals, iRay Technology, Taimei Medical Technology, Cytek Biosciences, Guoke Hengtai, Connetics Therapeutics, Convoy Therapeutics, Yidao Bio, Eastern Speech, and Cardea Bio.

Weidu Investment, a young and dynamic venture capital firm, adheres to the philosophy of “helping entrepreneurs journey from this shore to the other,” with a focus on early-stage investments in the healthcare sector. The Weidu team boasts extensive industry experience and medical resources, dedicating itself to accompanying portfolio companies throughout their growth journey and providing comprehensive empowerment at every stage. Weidu Investment prioritizes the cross-disciplinary application of emerging technologies—such as biotechnology, artificial intelligence, and internet technologies—in the medical field. It pursues more precise, efficient, personalized, and intelligent diagnostic and therapeutic methods driven by new technologies, as well as model innovations propelled by technological advancements. Weidu Investment aspires to work side-by-side with entrepreneurs to shape the new healthcare landscape of the digital era.

YuanSheng Venture Capital is an investment firm focused on early- and growth-stage companies in the healthcare sector. Headquartered at Suzhou BioBAY, it maintains a global reach. The firm currently manages approximately RMB 6 billion in assets and has completed investments in more than 100 high-quality projects, primarily spanning novel drug development, medical devices, in vitro diagnostics (IVD), and healthcare services. It has delivered substantial investment returns and has been repeatedly recognized as one of China’s Top 10 Venture Capital Funds in Healthcare and among China’s Most Active Healthcare Investment Institutions. YuanSheng Venture Capital brings together a team of seasoned professional investors and world-class scientific advisors, with extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry and related sectors. Leveraging its focused strategy and rich industry resources, YuanSheng Venture Capital is committed to becoming one of China’s most successful healthcare and pharmaceutical venture capital funds.